Dr. Raj Shah, S16978, Dr. Abhishek Desai, Dr. Girish Shiva Rao, Dr. Amit Jain, Dr.Mariam Doctor
Aim : To evaluate the safety profile of Razumab (Ranibizumab biosimilar) in clininal practice.
Methods : Prospective study for Incidence of ocular or nonocular adverse events (AEs) and serious AEs to Razumab (0.5mg) was done and patients followed up for atleast 12 weeks. All 48 patients received atleast 3 injections at monthly interval
Results : Of the 48 patients injected intravitreally with Razumab, 32 were males and 16 females.
The common indications for injection were CNVM followed by DME, BRVO, CRVO.
The only adverse reaction noted was transient rise in IOP in 1 patient.
Conclusion : Razumab is safe and cost effective alternative with similar safety profile as Lucentis/Accentrix. Further long term follow up and larger sample size required to know its safety profile.